2:19cv4959 • October 23, 2019
Class Period Start
March 10, 2019
Class Period End
December 16, 2019
PSLRA Deadline
December 23, 2019
Case Allegations
10b5
Statutes of Repose
Mar 10, 2022
Country
United States
Court
Federal Court
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
July 30, 2021
Settlement Fund
$4,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased or otherwise acquired Zynerba Pharmaceuticals, Inc. (“Zynerba” or the “Company”) securities between March 11, 2019 and September 17, 2019, both dates inclusive
Claim Administrator
Strategic Claims Services
Zynerba Pharmaceuticals, Inc. Securities Litigation c/o Strategic Claims Services P.O. Box 230
600 N. Jackson St., Ste. 205
Media, PA 19063
+1 866-274-4004
[email protected]
Settlement Website
https://www.strategicclaims.net/zynerba/Hearing Date
August 10, 2021
Opt-out Deadline
August 10, 2021
Settlement Note
Download hereProof Of Claim
Download here
Mar 2, 2022
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Sep 16, 2021
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
May 12, 2021
Preliminary Approval of Settlement
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
May 12, 2021
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Nov 25, 2020
The court has denied the defendants' request to dismiss the lawsuit. The case can now move forward to the next stage of litigation.
Jun 9, 2020
Apr 23, 2020
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Mar 9, 2020
A new complaint has been filed on behalf of certain investors in Zynerba Pharmaceuticals, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Jan 9, 2020
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Jan 8, 2020
Oct 23, 2019
A securities fraud class action complaint has been filed on behalf of certain investors in Zynerba Pharmaceuticals, Inc..
TOP
